Moreover, the clinical trial carried by Mau-Soerensen et al., (2014) among advanced metastatic CRC patients and used oral KPT-330 for 28 days confirmed the valuable of XPO1 inhibitors in line of disease stability for advanced staged CRC patients. This evidence concerns the gene XPO1 and colorectal carcinoma.